A hot new health startup just inked a deal with a major insurer, and it could shake up the whole medical testing industry
The move strikes a blow to traditional lab testing companies like Quest Diagnostics Inc. and Laboratory Corp. of America Holdings.
The startup, which is valued at $9 billion, also plans to open "wellness centers" on the East Coast, according to the company's billionaire CEO Elizabeth Holmes.
Theranos claims its fingerprick testing is just as accurate as drawing blood from a vein, but costs significantly less. "We want to be the highest-quality, lowest-cost lab service, period," Holmes told Bloomberg.
The new blood tests will be available to Capital BlueCross customers at its two retail stores, as well as any locations opened by the startup, said Capital's CEO Gary St. Hilaire.
Theranos won FDA approval last week for its herpes test, an important victory for a company that has been criticized for being secretive about how its blood tests work.
While the deal with Capital BlueCross is its biggest yet, the startup already has partnerships with the drugstore chain Walgreens Boots Alliance Inc., as well as contracts with health-care providers like the Cleveland Clinic and Intermountain Healthcare, a 22-hospital system in Utah and Idaho. It also has a deal for two wellness centers located in Arizona.
NOW WATCH: 5 Health Myths That Are Completely Wrong
- 2 states where home prices are falling because there are too many houses and not enough buyers
- US buys 81 Soviet-era combat aircraft from Russia's ally costing on average less than $20,000 each, report says
- A couple accidentally shipped their cat in an Amazon return package. It arrived safely 6 days later, hundreds of miles away.
- 9 health benefits of drinking sugarcane juice in summer
- 10 benefits of incorporating almond oil into your daily diet
- From heart health to detoxification: 10 reasons to eat beetroot
- Why did a NASA spacecraft suddenly start talking gibberish after more than 45 years of operation? What fixed it?
- ICICI Bank shares climb nearly 5% after Q4 earnings; mcap soars by ₹36,555.4 crore